These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17198975)

  • 1. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW; Murcko MA
    J Med Chem; 1996 Jul; 39(15):2887-93. PubMed ID: 8709122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of known drug space. Natural products, their derivatives and synthetic drugs.
    Bade R; Chan HF; Reynisson J
    Eur J Med Chem; 2010 Dec; 45(12):5646-52. PubMed ID: 20888084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand efficiency indices as guideposts for drug discovery.
    Abad-Zapatero C; Metz JT
    Drug Discov Today; 2005 Apr; 10(7):464-9. PubMed ID: 15809192
    [No Abstract]   [Full Text] [Related]  

  • 10. Model-free drug-likeness from fragments.
    Ursu O; Oprea TI
    J Chem Inf Model; 2010 Aug; 50(8):1387-94. PubMed ID: 20726597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Known drug space as a metric in exploring the boundaries of drug-like chemical space.
    Mirza A; Desai R; Reynisson J
    Eur J Med Chem; 2009 Dec; 44(12):5006-11. PubMed ID: 19782440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based drug design: how big is too big?
    Hajduk PJ
    J Med Chem; 2006 Nov; 49(24):6972-6. PubMed ID: 17125250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead optimization in the nondrug-like space.
    Zhao H
    Drug Discov Today; 2011 Feb; 16(3-4):158-63. PubMed ID: 21147254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the chemical properties of drugs and FEMA/FDA notified GRAS chemical compounds used in the food industry.
    Sprous DG; Salemme FR
    Food Chem Toxicol; 2007 Aug; 45(8):1419-27. PubMed ID: 17368904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive activity profiling of drugs by topological-fragment-spectra-based support vector machines.
    Kawai K; Fujishima S; Takahashi Y
    J Chem Inf Model; 2008 Jun; 48(6):1152-60. PubMed ID: 18533712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.
    Perola E
    J Med Chem; 2010 Apr; 53(7):2986-97. PubMed ID: 20235539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
    Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
    Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex molecules: do they add value?
    Selzer P; Roth HJ; Ertl P; Schuffenhauer A
    Curr Opin Chem Biol; 2005 Jun; 9(3):310-6. PubMed ID: 15939334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
    Aronov AM; McClain B; Moody CS; Murcko MA
    J Med Chem; 2008 Mar; 51(5):1214-22. PubMed ID: 18288794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.